Review

Management of painful vaso-occlusive crisis of sickle-cell anemia: Consensus opinion

Shaker A. Mousa, Abbdulkareem Al Momen, Faisal Al Sayegh, Soad Al Jaouni, Zaki Nasrullah, Hussein Al Saeed, Abbas Alabdullatif, Mohamad Al Sayegh, Hazaa Al Zahrani, Maha Hegazi, Amin Al Mohamadi, A. Alsulaiman, Awad Omer, Salam Al Kindi, Ahamd Tarawa, Fahad Al Othman, Mohammad Qari

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Sickle-cell disease (SCD) is a wide-spread inherited hemolytic anemia that is due to a point mutation, leading to the substitution of valine for glutamic acid, causing a spectrum of clinical manifestations in addition to hemolysis and anemia. Acute painful crisis is a common sequela that can cause significant morbidity and negatively impact the patients quality of life. Remarkable improvements in the understanding of the pathogenesis of this clinical syndrome and the role of cell adhesion, inflammation, and coagulation in acute painful crisis have led to changes in the management of pain. Due to the endemic nature of SCD in various parts of the Middle East, a group of physicians and scientists from the United States and Middle East recently met to draw up a set of suggested guidelines for the management of acute painful crisis that are reflective of local and international experience. This review brings together a detailed etiology, the pathophysiology, and clinical presentation of SCD, including the differential diagnoses of pain associated with the disease, with evidence-based recommendations for pain management and the potential impact of low-molecular-weight heparin (LMWH), from the perspective of physicians and scientists with long-term experience in the management of a large number of patients with SCD.

Original languageEnglish
Pages (from-to)365-376
Number of pages12
JournalClinical and Applied Thrombosis/Hemostasis
Volume16
Issue number4
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Sickle Cell Anemia
Consensus
Middle East
Pain Management
Physicians
Low Molecular Weight Heparin
Hemolytic Anemia
Valine
Hemolysis
Point Mutation
Cell Adhesion
Anemia
Glutamic Acid
Differential Diagnosis
Quality of Life
Guidelines
Inflammation
Morbidity
Pain

Keywords

  • diagnosis
  • guidelines
  • low-molecular-weight heparin
  • management
  • painful crisis
  • prophylaxis
  • sickle cell
  • vaso-occlusive crisis

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Mousa, S. A., Momen, A. A., Sayegh, F. A., Jaouni, S. A., Nasrullah, Z., Saeed, H. A., ... Qari, M. (2010). Review: Management of painful vaso-occlusive crisis of sickle-cell anemia: Consensus opinion. Clinical and Applied Thrombosis/Hemostasis, 16(4), 365-376. https://doi.org/10.1177/1076029609352661

Review : Management of painful vaso-occlusive crisis of sickle-cell anemia: Consensus opinion. / Mousa, Shaker A.; Momen, Abbdulkareem Al; Sayegh, Faisal Al; Jaouni, Soad Al; Nasrullah, Zaki; Saeed, Hussein Al; Alabdullatif, Abbas; Sayegh, Mohamad Al; Zahrani, Hazaa Al; Hegazi, Maha; Mohamadi, Amin Al; Alsulaiman, A.; Omer, Awad; Kindi, Salam Al; Tarawa, Ahamd; Othman, Fahad Al; Qari, Mohammad.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 16, No. 4, 08.2010, p. 365-376.

Research output: Contribution to journalArticle

Mousa, SA, Momen, AA, Sayegh, FA, Jaouni, SA, Nasrullah, Z, Saeed, HA, Alabdullatif, A, Sayegh, MA, Zahrani, HA, Hegazi, M, Mohamadi, AA, Alsulaiman, A, Omer, A, Kindi, SA, Tarawa, A, Othman, FA & Qari, M 2010, 'Review: Management of painful vaso-occlusive crisis of sickle-cell anemia: Consensus opinion', Clinical and Applied Thrombosis/Hemostasis, vol. 16, no. 4, pp. 365-376. https://doi.org/10.1177/1076029609352661
Mousa, Shaker A. ; Momen, Abbdulkareem Al ; Sayegh, Faisal Al ; Jaouni, Soad Al ; Nasrullah, Zaki ; Saeed, Hussein Al ; Alabdullatif, Abbas ; Sayegh, Mohamad Al ; Zahrani, Hazaa Al ; Hegazi, Maha ; Mohamadi, Amin Al ; Alsulaiman, A. ; Omer, Awad ; Kindi, Salam Al ; Tarawa, Ahamd ; Othman, Fahad Al ; Qari, Mohammad. / Review : Management of painful vaso-occlusive crisis of sickle-cell anemia: Consensus opinion. In: Clinical and Applied Thrombosis/Hemostasis. 2010 ; Vol. 16, No. 4. pp. 365-376.
@article{a56547018e014753b6876b0cfe71f186,
title = "Review: Management of painful vaso-occlusive crisis of sickle-cell anemia: Consensus opinion",
abstract = "Sickle-cell disease (SCD) is a wide-spread inherited hemolytic anemia that is due to a point mutation, leading to the substitution of valine for glutamic acid, causing a spectrum of clinical manifestations in addition to hemolysis and anemia. Acute painful crisis is a common sequela that can cause significant morbidity and negatively impact the patients quality of life. Remarkable improvements in the understanding of the pathogenesis of this clinical syndrome and the role of cell adhesion, inflammation, and coagulation in acute painful crisis have led to changes in the management of pain. Due to the endemic nature of SCD in various parts of the Middle East, a group of physicians and scientists from the United States and Middle East recently met to draw up a set of suggested guidelines for the management of acute painful crisis that are reflective of local and international experience. This review brings together a detailed etiology, the pathophysiology, and clinical presentation of SCD, including the differential diagnoses of pain associated with the disease, with evidence-based recommendations for pain management and the potential impact of low-molecular-weight heparin (LMWH), from the perspective of physicians and scientists with long-term experience in the management of a large number of patients with SCD.",
keywords = "diagnosis, guidelines, low-molecular-weight heparin, management, painful crisis, prophylaxis, sickle cell, vaso-occlusive crisis",
author = "Mousa, {Shaker A.} and Momen, {Abbdulkareem Al} and Sayegh, {Faisal Al} and Jaouni, {Soad Al} and Zaki Nasrullah and Saeed, {Hussein Al} and Abbas Alabdullatif and Sayegh, {Mohamad Al} and Zahrani, {Hazaa Al} and Maha Hegazi and Mohamadi, {Amin Al} and A. Alsulaiman and Awad Omer and Kindi, {Salam Al} and Ahamd Tarawa and Othman, {Fahad Al} and Mohammad Qari",
year = "2010",
month = "8",
doi = "10.1177/1076029609352661",
language = "English",
volume = "16",
pages = "365--376",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Review

T2 - Management of painful vaso-occlusive crisis of sickle-cell anemia: Consensus opinion

AU - Mousa, Shaker A.

AU - Momen, Abbdulkareem Al

AU - Sayegh, Faisal Al

AU - Jaouni, Soad Al

AU - Nasrullah, Zaki

AU - Saeed, Hussein Al

AU - Alabdullatif, Abbas

AU - Sayegh, Mohamad Al

AU - Zahrani, Hazaa Al

AU - Hegazi, Maha

AU - Mohamadi, Amin Al

AU - Alsulaiman, A.

AU - Omer, Awad

AU - Kindi, Salam Al

AU - Tarawa, Ahamd

AU - Othman, Fahad Al

AU - Qari, Mohammad

PY - 2010/8

Y1 - 2010/8

N2 - Sickle-cell disease (SCD) is a wide-spread inherited hemolytic anemia that is due to a point mutation, leading to the substitution of valine for glutamic acid, causing a spectrum of clinical manifestations in addition to hemolysis and anemia. Acute painful crisis is a common sequela that can cause significant morbidity and negatively impact the patients quality of life. Remarkable improvements in the understanding of the pathogenesis of this clinical syndrome and the role of cell adhesion, inflammation, and coagulation in acute painful crisis have led to changes in the management of pain. Due to the endemic nature of SCD in various parts of the Middle East, a group of physicians and scientists from the United States and Middle East recently met to draw up a set of suggested guidelines for the management of acute painful crisis that are reflective of local and international experience. This review brings together a detailed etiology, the pathophysiology, and clinical presentation of SCD, including the differential diagnoses of pain associated with the disease, with evidence-based recommendations for pain management and the potential impact of low-molecular-weight heparin (LMWH), from the perspective of physicians and scientists with long-term experience in the management of a large number of patients with SCD.

AB - Sickle-cell disease (SCD) is a wide-spread inherited hemolytic anemia that is due to a point mutation, leading to the substitution of valine for glutamic acid, causing a spectrum of clinical manifestations in addition to hemolysis and anemia. Acute painful crisis is a common sequela that can cause significant morbidity and negatively impact the patients quality of life. Remarkable improvements in the understanding of the pathogenesis of this clinical syndrome and the role of cell adhesion, inflammation, and coagulation in acute painful crisis have led to changes in the management of pain. Due to the endemic nature of SCD in various parts of the Middle East, a group of physicians and scientists from the United States and Middle East recently met to draw up a set of suggested guidelines for the management of acute painful crisis that are reflective of local and international experience. This review brings together a detailed etiology, the pathophysiology, and clinical presentation of SCD, including the differential diagnoses of pain associated with the disease, with evidence-based recommendations for pain management and the potential impact of low-molecular-weight heparin (LMWH), from the perspective of physicians and scientists with long-term experience in the management of a large number of patients with SCD.

KW - diagnosis

KW - guidelines

KW - low-molecular-weight heparin

KW - management

KW - painful crisis

KW - prophylaxis

KW - sickle cell

KW - vaso-occlusive crisis

UR - http://www.scopus.com/inward/record.url?scp=77954930750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954930750&partnerID=8YFLogxK

U2 - 10.1177/1076029609352661

DO - 10.1177/1076029609352661

M3 - Article

VL - 16

SP - 365

EP - 376

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 4

ER -